Literature DB >> 874324

Human factor D of the alternative complement pathway: purification and characterization.

J E Volanakis, R E Schrohenloher, R M Stroud.   

Abstract

D was purified to homogeneity from outdated human plasma by successive chromatography on Bio Rex 70, Sephadex G-200, Bio Rex 70, and Sephadex G-75. Column fractions were monitored for D activity by a hemolytic diffusion plate assay. The overall yield was approximately 4% by activity. A m.w. of 22,900 daltons was established by sedimentation equilibrium. Amino acid analyses have been obtained and Isoleucine has been determined as the NH2-terminus. Incubation of D with purified B and CoVF in the presence of Mg++ resulted in cleavage of B, as judged by SDS-polyacrylamide gel electrophoresis and immunoelectrophoresis. D hydrolyzed certain synthetic amino acid esters of arginine, lysine, and tyrosine. Benzoyl-L-arginine methyl esters (BAME) was the most sensitive substrate for D among those tested. The substrate profile of D was dinstinct when compared to that of CIs, CIr, plasmin, urokinase, and trypsin. Both the enzymatic and hemolytic activity of D were irreversibly inhibited by treatment with 10 mM DFP as well as by reduction and alkylation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874324

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site.

Authors:  D M Johnson; J Gagnon; K B Reid
Journal:  Biochem J       Date:  1980-06-01       Impact factor: 3.857

2.  In vivo changes in complement induced with peptidoglycan-polysaccharide polymers from streptococcal cell walls.

Authors:  J D Lambris; J B Allen; J H Schwab
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

3.  Complement receptors on Raji cells. The presence of a new type of C3 receptor.

Authors:  T Okuda; T Tachibana
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

4.  Activation of the first component of human complement (C1) by antibody-antigen aggregates.

Authors:  A W Dodds; R B Sim; R R Porter; M A Kerr
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

5.  Purification and partial characterization of rat factor D.

Authors:  B C Baker; C J Campbell; C J Grinham; G Turcatti
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

6.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

7.  Partial amino acid sequence of human factor D:homology with serine proteases.

Authors:  J E Volanakis; A Bhown; J C Bennett; J E Mole
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

8.  The catalytic chain of human complement subcomponent C1r. Purification and N-terminal amino acid sequences of the major cyanogen bromide-cleavage fragments.

Authors:  G J Arlaud; J Gagnon; R R Porter
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

9.  Properdin factor D: effects on thrombin-induced platelet aggregation.

Authors:  A E Davis; D M Kenney
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

10.  Functional properties of membrane cofactor protein of complement.

Authors:  T Seya; J P Atkinson
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.